Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Atkins

Showing results (311-320 of 493) with videos related to

Pageof 50
Sort By:
Journal of Oncology|March 1, 2022
Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the PandemicCatherine Lai, Arnold L Potosky, Colleen McGuire, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2Richard W Joseph, Jeanette E Eckel-Passow, Ruchi Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)Lisa H Butterfield, Fengmin Zhao, Sandra Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)David H Lawson, Sandra Lee, Fengmin Zhao, et al.
Radiology|December 1, 2020
Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell CarcinomaLeo L Tsai, Rupal S Bhatt, Meaghan F Strob, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanomaGeoffrey T Gibney, Jacob Zaemes, Shelly Shand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.
European Urology|June 26, 2012
BRAF mutations in metanephric adenoma of the kidneyToni K Choueiri, John Cheville, Emanuele Palescandolo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark, Jessica Mehrabi, Jeffrey A Sosman, et al.
Pageof 50

Showing results (311-320 of 493) with videos related to

Sort By:
Pageof 50
Journal of Oncology|March 1, 2022
Incidence and Durability of SARS-CoV-2 Antibodies in Patients with Cancer and Health Care Workers following the First Wave of the PandemicCatherine Lai, Arnold L Potosky, Colleen McGuire, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 24, 2012
Characterizing the clinical benefit of ipilimumab in patients who progressed on high-dose IL-2Richard W Joseph, Jeanette E Eckel-Passow, Ruchi Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)Lisa H Butterfield, Fengmin Zhao, Sandra Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2015
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)David H Lawson, Sandra Lee, Fengmin Zhao, et al.
Radiology|December 1, 2020
Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell CarcinomaLeo L Tsai, Rupal S Bhatt, Meaghan F Strob, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanomaGeoffrey T Gibney, Jacob Zaemes, Shelly Shand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerKim Margolin, Michael B Atkins, Janice P Dutcher, et al.
European Urology|June 26, 2012
BRAF mutations in metanephric adenoma of the kidneyToni K Choueiri, John Cheville, Emanuele Palescandolo, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 1, 2007
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group studyJoseph I Clark, Jessica Mehrabi, Jeffrey A Sosman, et al.
Pageof 50